Symphogen captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody compositions. Symphogen is maturing a diversified pipeline of internal and partnered products across indications including cancer and infectious disease.
Antibodies are an important part of the immune system, whose role is to help the body prevent and fight infections and diseases. When a foreign and potentially harmful object (called an “antigen”), such as a bacteria, virus, or cancer cell, is in the human body, antibodies find and then either neutralize or destroy the invader.
The human body produces many different kinds of antibodies that are able to attach themselves to different parts of an antigen, which helps them completely eliminate these foreign objects. This is called a “polyclonal” response, because there is more than one type of antibody involved. The polyclonal antibodies that Symphogen develops mimic the natural human immune response. This means that they may have potential in preventing and treating infections, certain types of cancer, and other diseases.
Currently, the only available treatments that resemble a natural polyclonal immune response are immunoglobulins, which are generally isolated from blood of healthy or vaccinated donors, and in certain cases animals or donors who have recovered from a specific disease. Unfortunately, immunoglobulins can be associated with low effectiveness because only a fraction of the antibodies will be specific to a particular antigen; safety issues due to the risk of disease transmission; and supply shortages due to dependency on donor blood availability. Symphogen’s polyclonal antibodies are recombinant, meaning that they are produced using modern biotechnological processes on an industrial scale. This approach enables Symphogen to simultaneously generate a variety of antibodies, all specific to a particular disease. By using industrial equipment, Symphogen can quickly produce large quantities of these antibodies while avoiding the risks of disease transmission or donor supply shortages.
Symphogen’s proprietary technologies offers the discovery and production of unlimited amounts of highly purified, antigen-specific compositions of recombinant antibodies - a totally new class of therapeutic antibodies with a number of prominent advantages compared to existing antibody therapies.
Symphogen is located in 2000 m2 fully renovated and classified laboratory and office facilities at the Danish Technical University, Lyngby, immediately outside the center of Copenhagen, Denmark. The Company currently employs 70 people.
